Brian Atwood
Chairman chez ATRECA, INC.
Fortune : 767 589 $ au 31/03/2024
Profil
Brian G.
Atwood founded Glycomed, Inc. in 1987, where he worked as President & Chief Executive Officer in 1995, Versant Ventures I LLC in 1999, where he worked as Managing Director, Versant Venture Management LLC in 1999, where he worked as Managing Director, and various other companies.
Mr. Atwood also founded PE Corp.
(New York), where he worked as Director and Perkin-Elmer Cetus Instruments, where he worked as Director.
Mr. Atwood also currently works at CERo Therapeutics Holdings, Inc., as Chairman & Chief Executive Officer from 2024, Atreca, Inc., as Chairman from 2013, and Biotechnology Innovation Organization, as Director.
Mr. Atwood also formerly worked at Five Prime Therapeutics, Inc., as Chairman from 2012 to 2016, Veracyte, Inc., as Chairman from 2013 to 2016, Locust Walk Acquisition Corp., as Chairman in 2021, and various other companies.
Mr. Atwood received his graduate degree from the University of California, Davis, undergraduate degree from the University of California, Irvine, and Masters Business Admin degree from Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
1,67% | 05/04/2024 | 248 735 ( 1,67% ) | 763 616 $ | 31/03/2024 |
ATRECA, INC. CLASS A
0,13% | 13/06/2023 | 49 654 ( 0,13% ) | 3 972 $ | 31/03/2024 |
Postes actifs de Brian Atwood
| Sociétés | Poste | Début |
|---|---|---|
| ATRECA, INC. | Chairman | 01/12/2013 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | - |
Anciens postes connus de Brian Atwood
| Sociétés | Poste | Fin |
|---|---|---|
| CLOVIS ONCOLOGY, INC. | Director/Board Member | 10/07/2023 |
| EFFECTOR THERAPEUTICS, INC. | Chairman | 01/08/2021 |
Cell Design Labs, Inc.
 Cell Design Labs, Inc. BiotechnologyHealth Technology Cell Design Labs, Inc. develops disruptive cell-based therapies for cancer and other devastating diseases. The company was founded by Brian G. Atwood and Fred E. Cohen in 2016 and is headquartered in Emeryville, CA. | Founder | 01/02/2018 |
| OPGEN, INC. | Director/Board Member | 08/06/2017 |
| VERACYTE, INC. | Chairman | 12/12/2016 |
Formation de Brian Atwood
| University of California, Davis | Graduate Degree |
| University of California, Irvine | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| OPGEN, INC. | Commercial Services |
| VERACYTE, INC. | Health Technology |
| ATRECA, INC. | Health Technology |
| PHASERX, INC. | Health Technology |
| Entreprise privées | 31 |
|---|---|
Glycomed, Inc.
 Glycomed, Inc. Pharmaceuticals: MajorHealth Technology Glycomed, Inc. discovers and developes pharmaceuticals based on complex carbohydrates. The company's drug discovery strategy utilizes medicinal chemistry to identify biologically active small molecules for therapeutic use. The company was founded by Brian G. Atwood in 1987 and is headquartered in San Diego, CA. | Health Technology |
Xenogen Corp.
 Xenogen Corp. Medical SpecialtiesHealth Technology Xenogen Corp. provides real time in-vivo imaging services and genetic modification technologies. Its products and technologies include an imaging system, software, and biological materials. Its solutions are designed to improve discovery and pre-clinical research in multiple therapeutic areas. The company was founded by Pamela Reilly Contag and Christopher H. Contag in 1995 and is headquartered in Alameda, CA. | Health Technology |
Pharmion Corp.
 Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Health Technology |
| Versant Ventures I LLC | |
ISB Accelerator Corp.
 ISB Accelerator Corp. Miscellaneous Commercial ServicesCommercial Services ISB Accelerator Corp. is involved in the study of biological systems to help identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. The company is located in Seattle, WA. | Commercial Services |
Theraclone Sciences, Inc.
 Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Commercial Services |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
| Versant Venture Capital III LP | Finance |
| Versant Ventures II LLC | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Groove Biopharma Corp.
 Groove Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Groove Biopharma Corp. focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) were involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma's core technology addressed a new avenue of nucleotide therapeutic drug discovery via modulation of cellular mirna. Used exclusive technology, Groove Biopharma were generated a series of lead candidates with the potential to be best-in-class therapeutics. By incorporated proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presented promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.The company was founded in 2008 and is headquartered in Seattle,UN. | Commercial Services |
Brentwood Venture Capital
 Brentwood Venture Capital Investment ManagersFinance Brentwood Venture Capital (brentwood) is a venture capital firm located in the US. The firm is the venture capital investment arm of Brentwood Associates, a Los Angeles-based private equity firm. it was founded in 1989 and is headquartered in Los Angeles,California. | Finance |
| PE Corp. (New York) | Health Technology |
Brentwood Associates
 Brentwood Associates Investment ManagersFinance Brentwood Associates is a Private Equity firm founded in 1984 by William M. Barnum and B. Kipling Hagopian. The firm is headquartered in Los Angeles, CA. | Finance |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Helicos Biosciences Corp.
 Helicos Biosciences Corp. Miscellaneous Commercial ServicesCommercial Services Helicos BioSciences Corp. is a life sciences company focused on innovative genetic analysis technologies and the monetization of those technologies and related intellectual property. The company was founded by Stanley N. Lapidus, Stephen D. Quake and Noubar B. Afeyan on May 9, 2003 and is headquartered in Cambridge, MA. | Commercial Services |
Saegis Pharmaceuticals, Inc.
 Saegis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Saegis Pharmaceuticals, Inc. developed drug therapeutics. Its phase II SGS742 clinical drug treated diseases such as mild cognitive impairment and attention deficit hyperactivity disorder. Its second SGS742 clinical trial provided coronary artery bypass surgery. The company was founded in 1999 and was headquartered in Half Moon Bay, CA. | Health Technology |
Mallinckrodt Hospital Products, Inc.
 Mallinckrodt Hospital Products, Inc. Pharmaceuticals: MajorHealth Technology Mallinckrodt Hospital Products, Inc. operates as a biopharmaceutical company, which develops and commercializes proprietary product candidates used in the hospital setting. The firm offers OFIRMEV (acetaminophen injection), a proprietary intravenous formulation of acetaminophen for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever. The company was founded by Theodore R. Schroeder, David A. Socks, and Cam L. Garner on May 26, 2004 and is headquartered in Hazelwood, MO. | Health Technology |
ForteBio, Inc.
 ForteBio, Inc. Medical SpecialtiesHealth Technology Pall ForteBio Corp. develops analytical systems that enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics, and concentration. The company was founded in October 2001 and is headquartered in Menlo Park, CA. | Health Technology |
| Versant Ventures III LLC | |
Accelerator Services Corp
 Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Finance |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
| Versant Ventures IV LLC | |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Spark Diagnostics, Inc.
 Spark Diagnostics, Inc. Medical/Nursing ServicesHealth Services Spark Diagnostics, Inc. provides diagnostic services. It uses sequencing technology to diagnose diseases. The company was founded by Jessica Owens in 2011 and is headquartered in San Francisco, CA. | Health Services |
| Perkin-Elmer Cetus Instruments | |
Cell Design Labs, Inc.
Cell Design Labs, Inc. BiotechnologyHealth Technology Cell Design Labs, Inc. develops disruptive cell-based therapies for cancer and other devastating diseases. The company was founded by Brian G. Atwood and Fred E. Cohen in 2016 and is headquartered in Emeryville, CA. | Health Technology |
Locust Walk Acquisition Corp.
 Locust Walk Acquisition Corp. Financial ConglomeratesFinance Locust Walk Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on October 2, 2020 and is headquartered in Boston, MA. | Finance |
Phoenix Biotech Acquisition Corp.
 Phoenix Biotech Acquisition Corp. Financial ConglomeratesFinance Phoenix Biotech Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on June 8, 2021 and is headquartered in Oakland, CA. | Finance |
| Cadence Pharmaceuticals , Inc. |
